U.S. Markets close in 3 hrs 1 min

Aeglea BioTherapeutics, Inc. (AGLE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.09-0.14 (-1.76%)
As of 12:57PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.23
Open8.36
Bid8.04 x 800
Ask8.10 x 900
Day's Range7.99 - 8.36
52 Week Range3.50 - 11.38
Volume83,689
Avg. Volume279,304
Market Cap387.571M
Beta (5Y Monthly)1.69
PE Ratio (TTM)N/A
EPS (TTM)-1.76
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.63
  • Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria
    PR Newswire

    Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria

    Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to ACN00177 for the treatment of Homocystinuria, a serious metabolic disorder characterized by elevated plasma homocysteine which leads to a wide range of life-altering complications and reduced life expectancy. ACN00177 is a novel engineered human enzyme therapy designed to lower the total level of homocysteine in the plasma. Aeglea initiated a Phase 1/2 clinical trial earlier this year to investigate ACN00177 for the treatment of Homocystinuria.

  • Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference
    PR Newswire

    Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference

    Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced updated timing for its Fireside Chat presentation at an upcoming investor conference hosted by Evercore.

  • Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences
    PR Newswire

    Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences

    Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in fireside chats at two investor conferences in December 2020.